Thirty Madison, a direct-to-consumer health care company for people with chronic conditions, raised $140 million in a Series C funding round led by new investor HealthQuest Capital. With this new round of funding, Thirty Madison will expand access to its specialist-level care model to the millions of Americans with chronic conditions. Thirty Madison provides four condition-specific brand platforms: Keeps for men’s hair loss, Evens for gastrointestinal conditions, Cove for migraine, and Picnic for allergies. Each brand provides virtual physician visits, a range of therapeutic treatments, tools, and individually tailored educational content. Prescription and over-the-counter medications are also available through the platform.
With the new funding, Thirty Madison intends to enhance the capabilities of its proprietary platform underpinning its care model as well as launching new brands focused on driving superior health outcomes and better consumer experiences across conditions. The investment will enable Thirty Madison to reach consumers not only directly, but also through their employers and health care payor networks via innovative partnerships.
Mousse Partners and Bracket Capital also participated in the funding round, along with existing investors Polaris Partners, Johnson & Johnson Innovation – JJDC, Inc., Northzone, Greycroft, and others. Randy Scott, partner at HealthQuest Capital will join Jason Stoffer, Partner at Maveron, and Amy Schulman, managing partner at Polaris Partners, as a member of Thirty Madison’s Board of Directors.
Since its founding in 2017, Thirty Madison has raised a total of $210 million to date and is now valued at over $1 billion. In 2020, Thirty Madison tripled its revenue, and the company now serves hundreds of thousands of consumers across its offerings.
This was reported by Thirty Madison on June 2, 2021.